RDNT at a glance
RadNet, Inc. (RDNT, SEC CIK 790526) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), RadNet, Inc. (RDNT) reported revenue of $2.0 billion (up 11.5% from FY2024) and a net loss of $18.7 million. Diluted EPS was -$0.25.
- As of September 30, 2026, 31 institutional investment managers tracked by SignalX reported holding RadNet, Inc. (RDNT) shares worth $2.5 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Patel Mital on November 11, 2026 of 44,661 shares at $78.51 per share.
- In the last 90 days, RDNT insiders reported 0 open-market purchases ($0) and 1 open-market sale ($3.5M) on Form 4, a net sale of $3.5M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.0B
- +11.5% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$3.5M
- 13F holders
- 31 funds
- $2.5B · −1 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Diagnostic imaging services revenue from patients and third-party payors under fee-for-service and capitation contracts
- Emphasis on capitation arrangements earning per-enrollee monthly revenue for making imaging services available to health plan members
- Business combination accounting impacting goodwill and asset valuations with possible adjustments up to one year post-acquisition
- Accounts receivable primarily from insurance and government programs, with continuous monitoring and allowances for credit losses
- No introduction of new products or segments but focus on contractual revenue estimation and collection practices
Risk Factors
- CMS 2026 Physician Fee Schedule final rule may reduce Medicare reimbursement rates and imaging volumes starting CY 2026
- Significant exposure to California natural disasters: headquarters and 100+ centers vulnerable to wildfires, blackouts, earthquakes
- Dependence on contracted radiology groups for managed care contracts; termination risks revenue loss and competitive position
- Competition from private equity-backed chains and hospitals, risking market share due to their greater financial resources and newer equipment
- Majority of indebtedness at variable rates; rising interest rates increase borrowing costs and may reduce profitability
Management Discussion & Analysis
- Revenue $2.04B in 2025, up 11.5% YoY from $1.83B in 2024; Imaging Center revenue $1.99B up 10.9% YoY
- Operating margin 3.0% in 2025 vs 5.7% in 2024; net income margin 0.8% in 2025 vs 2.0% in 2024
- Best performing segment: Imaging Center $1.99B revenue (+$196M, +10.9% YoY); worst: Digital Health $92.7M revenue (+$27M, +41.0% YoY) but smaller scale
- Operating expenses rose 13.2% to $1.89B in 2025 driven by volume growth, wages, and medical supplies; stock comp increased 66.3% to $44.7M
- Capital allocation: acquisitions totaled $229.8M in 2025 (iCAD $110.7M, CIMAR $37M, See-Mode $28.9M), no data on buybacks/dividends disclosed
- Management highlights expansion in Digital Health via AI acquisitions; identifies risks from wage inflation, supply costs, and weather impacting Q1 volumes
AI summary of the RDNT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $638.3M, up 22.1% YoY from $522.9M, driven by Imaging Centers revenue of $617.0M
- Segment profit $83.8M vs $69.7M YoY, with Imaging Centers $96.9M vs $74.0M and Digital Health loss $13.1M vs $4.3M
- Best performer: Digital Health Clinical AI revenue up 50.9%; worst: Digital Health net loss $16.1M vs $7.5M
- Cash $750.6M vs $767.2M at December 31, 2025; operating cash flow $263.6M vs $214.7M
- Investing used $487.6M, including $249.2M higher acquisition spending; near-term Digital Health losses expected during integration and growth investment
Risk Factors
- Newly added merger risk: ONRAD acquisition announced October 26, 2026, subject to regulatory approvals and closing conditions
- Regulatory risk: Required clearances could significantly delay or prevent merger completion
- Legal risk: Merger-related shareholder litigation could impose substantial costs or enjoin closing
- Operational risk: Business partners may renegotiate or pursue alternatives amid merger uncertainty
- Financial risk: Non-recurring advisory, integration, facilities, and systems costs may exceed expectations
AI summary of the RDNT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- RadNet reported third-quarter fiscal 2026 financial results for the period ended September 30, 2026
- Full operating metrics and management commentary are contained in Exhibit 99.1, the accompanying earnings release
Item EX-99.1: Item EX-99.1
- Q3 revenue rose 22.1% to $638.3M and Adjusted EBITDA 23.8% to $105.0M, supporting stronger operating momentum
- Adjusted diluted EPS increased to $0.30 from $0.24, while GAAP diluted EPS declined to $0.05 from $0.07
Item EX-99.1: Item EX-99.1
- Acquisition of ONRAD expands RadNet into hospital-based teleradiology and professional staffing, creating a third Radiology Professional Services segment
- First-year contribution target: $190M-$200M revenue and $60M-$65M Adjusted EBITDA, implying a capital-light, high-margin growth platform
Item 3.02: Unregistered Sales of Equity Securities
- Item 3.02 contains no separate equity-sale details
- Investors should review Item 1.01’s “Merger Agreement” section for the referenced transaction terms
Item 7.01: Regulation FD Disclosure
- RadNet announced entry into a merger agreement, signaling a potentially material change in ownership or corporate structure
- Investor webcast and conference call scheduled for October 27, 2026 at 8:00 A.M. Eastern
Item 1.01: Entry into a Material Definitive Agreement
- RadNet to acquire OnRad, a teleradiology provider, in a transaction expected to close in early 2027
- Consideration: $350 million cash, subject to adjustments, plus 5 million RadNet shares
Item 8.01: Other Events
- Resale registration for up to 34,069 RadNet shares issued to See-Mode sellers
- Shares represent milestone-based consideration under the June 2, 2025 See-Mode acquisition agreement
AI summaries of RDNT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RDNT
Don't miss the next RDNT filing
- Alerts as it files. A push when RDNT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RDNT, by share count.
- Ask anything. An AI agent that reads every RDNT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Patel Mital | G | Nov 12, 2026 | 640 | - |
| Patel Mital | Sell | Nov 11, 2026 | 44,661 | $78.51 |
| SWARTZ DAVID L | Sell | Jun 18, 2026 | 2,699 | $53.89 |
| Wesdorp Cornelis | Sell | Jun 16, 2026 | 4,750 | $58.11 |
| Berger Howard G | G | Jun 16, 2026 | 90 | - |
| Forthuber Stephen M | Sell | Jun 15, 2026 | 19,853 | $58.61 |
| Forthuber Stephen M | Sell | Jun 15, 2026 | 24,214 | $57.79 |
| Jacobs Laura Pastre | A | Jun 2, 2026 | 2,946 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $1.6B | $1.8B | $2.0B |
| Operating Income | $98.7M | $104.6M | $62.0M |
| Net Income | $3.0M | $2.8M | -$18.7M |
| Op. Margin | 6.1% | 5.7% | 3.0% |
| Net Margin | 0.2% | 0.2% | -0.9% |
| Balance Sheet | |||
| Total Assets | $2.7B | $3.3B | $3.8B |
| Equity | $630.7M | $902.3M | $1.1B |
| ROE | 0.5% | 0.3% | -1.7% |
| Per Share | |||
| EPS | $0.05 | $0.04 | $-0.25 |
| Cash Flow | |||
| Operating CF | - | $233.0M | $298.8M |
Source: XBRL data in RadNet, Inc. (RDNT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate RDNT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 31 | $2.52B |
| Q2 2026 | 32 | $2.21B |
| Q1 2026 | 33 | $1.94B |
| Q4 2025 | 30 | $2.46B |
| Q3 2025 | 30 | $2.44B |
| Q2 2025 | 29 | $1.72B |
| Q1 2025 | 26 | $1.04B |
| Q4 2024 | 23 | $1.29B |
- T. Rowe Price Group+440.2K (+10%)
- JPMorgan Chase & Co+232.0K (+229%)
- Morgan Stanley+216.2K (+23%)
- Invesco Ltd+213.6K (+13%)
- Ameriprise Financial+187.2K (+25%)
- Millennium Management−368.1K (-79%)
- Citigroup−112.9K (-86%)
- Principal Financial Group−86.8K (-8%)
- Raymond James Financial−66.1K (-16%)
- Vanguard Portfolio Management LLC−66.1K (-2%)
- Two Sigma Investments+14.4K
- Citadel Advisors LLC+7.7K
- Soros Fund Management−116.6K
- StoneX Group Inc.−13.4K
- FMR LLC (Fidelity)−11.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 234 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RDNT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 12, 2026 | - | - | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 26, 2026 | - | Analysis | - |
| 8-K | Aug 14, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 4 | Jun 3, 2026 | - | - | |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| SC 13G | May 15, 2026 | - | - | |
| 8-K | May 11, 2026 | - | Analysis | |
| 10-Q | May 11, 2026 | Mar 31, 2026 | Analysis | |
| 4 | May 6, 2026 | - | - | |
| SC 13G | Apr 29, 2026 | - | - | |
| 4 | Mar 23, 2026 | - | - | - |
| 4 | Mar 18, 2026 | - | - | - |
Related Health Care companies
- CDNA · CareDx, Inc.Services-Medical Laboratories
- CSTL · CASTLE BIOSCIENCES INCServices-Medical Laboratories
- CELC · Celcuity Inc.Services-Medical Laboratories
- FTRE · Fortrea Holdings Inc.Services-Medical Laboratories
- FLGT · Fulgent Genetics, Inc.Services-Medical Laboratories
- GRAL · GRAIL, Inc.Services-Medical Laboratories
- GH · Guardant Health, Inc.Services-Medical Laboratories
- LH · LabcorpServices-Medical Laboratories
RDNT SEC filings: frequently asked questions
Are RDNT insiders buying or selling?
In the last 90 days, RadNet, Inc. (RDNT) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $3.5 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold RDNT stock?
As of September 30, 2026, the largest RadNet, Inc. (RDNT) holders among the 13F filers tracked by SignalX were BlackRock ($759.8 million), T. Rowe Price Group ($340.7 million), Vanguard Portfolio Management LLC ($275.8 million), Vanguard Capital Management LLC ($220.2 million), State Street Corp ($199.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was RDNT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), RadNet, Inc. (RDNT) reported revenue of $2.0 billion (up 11.5% from FY2024) and a net loss of $18.7 million. Diluted EPS was -$0.25. The figures come from the XBRL data in the 10-K.
What are the main risks in RDNT's latest 10-K?
In the 10-K filed March 2, 2026, RadNet, Inc. (RDNT) flagged: CMS 2026 Physician Fee Schedule final rule may reduce Medicare reimbursement rates and imaging volumes starting CY 2026. Significant exposure to California natural disasters: headquarters and 100+ centers vulnerable to wildfires, blackouts, earthquakes. (AI summary of the Risk Factors section.)
What did RDNT report in its latest 8-K?
RadNet, Inc. (RDNT) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). RadNet reported third-quarter fiscal 2026 financial results for the period ended September 30, 2026.
What are the latest RDNT SEC filings?
RadNet, Inc. (RDNT) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 12, 2026.
What is RDNT's SEC CIK number?
RadNet, Inc. (RDNT)'s SEC Central Index Key (CIK) is 790526. EDGAR lists every RDNT filing under that number.
Ask anything about RDNT
The research agent reads RDNT's filings, financials, insider trades and 13F holders, then answers with sources.